Patents by Inventor Kumiko TSUIHIJI

Kumiko TSUIHIJI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092836
    Abstract: The present invention provides a cyclic peptide which comprises the amino acid sequence represented by formula (I) X1-His-Pro-X4-Leu-X6-X7-X8-Ser-X10-His-Phe??(I) in the cycle and has an activity to specifically bind to human CTLA-4, wherein X1, X4, X6, X7, X8 and X10 are each independently any amino acid.
    Type: Application
    Filed: September 30, 2020
    Publication date: March 21, 2024
    Applicant: GeneFrontier Corporation
    Inventors: Kanehisa KOJOH, Kumiko TSUIHIJI, Shizue KATOH, Mikiko NAKAMURA
  • Patent number: 10865247
    Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: December 15, 2020
    Assignees: GeneFrontier Corporation, National University Corporation Chiba University
    Inventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
  • Publication number: 20200199235
    Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 25, 2020
    Applicants: GeneFrontier Corporation, National University Corporation Chiba University
    Inventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
  • Publication number: 20190233521
    Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.
    Type: Application
    Filed: October 5, 2018
    Publication date: August 1, 2019
    Applicants: GeneFrontier Corporation, National University Corporation Chiba University
    Inventors: Kanehisa KOJOH, Akira MIYAKOSHI, Shizue KATOH, Kumiko TSUIHIJI, Yuki HAYAMI, Mikiko NAKAMURA, Toshinori NAKAYAMA, Chiaki IWAMURA
  • Patent number: 10301618
    Abstract: The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component. A nucleic acid encoding a non-target component constituting the protein multimer together with the target component is translated into the non-target component by adding the nucleic acid encoding the non-target component to the previously provided translation product to provide the non-target component. The non-target component then is associated with the target component contained in the target component-nucleic acid complex to form a protein multimer, thus affording the protein multimer-nucleic acid complex of the protein multimer and the nucleic acid encoding the target component.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: May 28, 2019
    Assignee: GeneFrontier Corporation
    Inventors: Kanehisa Kojoh, Takashi Kanamori, Shizue Katoh, Kumiko Tsuihiji
  • Patent number: 9617533
    Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 11, 2017
    Assignees: GeneFrontier Corporation, The Univeristy of Tokyo
    Inventors: Takashi Kanamori, Yuki Hayami, Kanehisa Kojoh, Takuya Ueda, Kumiko Tsuihiji, Tomoe Fuse, Mikiko Nakamura, Shizue Kato
  • Publication number: 20160168563
    Abstract: The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component. A nucleic acid encoding a non-target component constituting the protein multimer together with the target component is translated into the non-target component by adding the nucleic acid encoding the non-target component to the previously provided translation product to provide the non-target component. The non-target component then is associated with the target component contained in the target component-nucleic acid complex to form a protein multimer, thus affording the protein multimer-nucleic acid complex of the protein multimer and the nucleic acid encoding the target component.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Applicant: GeneFrontier Corporation
    Inventors: Kanehisa KOJOH, Takashi KANAMORI, Shizue KATOH, Kumiko TSUIHIJI
  • Patent number: 9289742
    Abstract: The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component. A nucleic acid encoding a non-target component constituting the protein multimer together with the target component is translated into the non-target component by adding the nucleic acid encoding the non-target component to the previously provided translation product to provide the non-target component. The non-target component then is associated with the target component contained in the target component-nucleic acid complex to form a protein multimer, thus affording the protein multimer-nucleic acid complex of the protein multimer and the nucleic acid encoding the target component.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: March 22, 2016
    Assignee: GeneFrontier Corporation
    Inventors: Kanehisa Kojoh, Takashi Kanamori, Shizue Katoh, Kumiko Tsuihiji
  • Publication number: 20160010079
    Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.
    Type: Application
    Filed: September 25, 2015
    Publication date: January 14, 2016
    Inventors: Takashi KANAMORI, Yuki HAYAMI, Kanehisa KOJOH, Takuya UEDA, Kumiko TSUIHIJI, Tomoe FUSE, Mikiko NAKAMURA, Shizue KATO
  • Patent number: 9175327
    Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: November 3, 2015
    Assignees: GeneFrontier Corporation, The University of Tokyo
    Inventors: Takashi Kanamori, Yuki Hayami, Kanehisa Kojoh, Takuya Ueda, Kumiko Tsuihiji, Tomoe Fuse, Mikiko Nakamura, Shizue Kato
  • Publication number: 20150118237
    Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 30, 2015
    Inventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
  • Publication number: 20120231496
    Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 13, 2012
    Applicants: THE UNIVERSITY OF TOKYO, GENEFRONTIER CORPORATION
    Inventors: Takashi KANAMORI, Yuki HAYAMI, Kanehisa KOJOH, Takuya UEDA, Kumiko TSUIHIJI, Tomoe FUSE, Mikiko NAKAMURA, Shizue KATO